Day 3 Program

Poster Spotlight 8: Novel Insights into Breast Cancer

Day 3: December 10, 2026

7:00 AM–8:30 AM CST

Hemisfair 3

Session Details

Moderator

Popi Siziopikou, University of Arizona, Tucson, AZ

Moderator

Amrita Basu, University of California San Francisco, San Francisco, CA

PS8-1

Does pleomorphic ILC exist? Quantitative digital nuclear morphometry, molecular correlates, and clinical outcomes challenge a long-standing histologic paradigm

Lounes Djerroudi, Memorial Sloan Kettering Cancer Center, New York, NY

PS8-2

Clinicopathologic Correlates of MammaPrint Risk Classification and Comparison with Oncotype DX in Invasive Lobular Carcinoma

Rachael Nakfoor, Cleveland Clinic, Cleveland, OH

PS8-3

Deep learning-based histomorphologic profiling reveals clinically relevant AI-defined breast cancer subgroups, including novel invasive lobular carcinoma phenotypes

Lounes Djerroudi, Memorial Sloan Kettering Cancer Center, New York, NY

PS8-4

Histology-specific performance of genomic and digital pathology risk models in TAILORx

Ngoc-Kim Nguyen, University of Chicago, Chicago, IL

PS8-5

Single-cell subtyping of invasive lobular breast cancer by multicolor immunofluorescence – prognostic impact of proliferative heterogeneity in hormone receptor-negative tumor cells

Sofia Born, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany

PS8-6

ILC, a Unique Subtype

Hannah Wen, Memorial Sloan Kettering Cancer Center, New York, NY

PS8-7

Hematoxylin-and-eosin-based AI risk stratification identifies patients with ER+/HER2- early-stage breast cancer who have a favorable treatment outcome on endocrine therapy alone, including those who meet NATALEE-like criteria: independent validation in ABCSG-8

Martin Filipits, Medical University of Vienna, Vienna, Austria

PS8-8

Multi-modal artificial intelligence (AI) predicts neoadjuvant response and long-term outcomes in HER2-positive early breast cancer (HER2+ EBC) treated with chemotherapy de-escalation strategies: analysis of the PHERGain trials.

Giulia Notini, IRCCS San Raffaele Hospital, Milan, Italy, Milano, Italy

PS8-9

Global Breast Cancer Screening Practices: Geographic Variation, Risk-Based Screening Implementation Gaps, and Clinician Perspectives on Artificial Intelligence

Berkay Demirors, University of Pittsburgh, Pittsburgh, PA

PS8-10

Artificial Intelligence (AI)-Based Identification of Invasive Lobular Carcinoma (ILC) Reveals Distinct Treatment and Recurrence Patterns in Two Randomized Breast Cancer Trials

Mishal Ali, University of Chicago, Chicago, IL

PS8-11

A Multimodal Clinical, Genomic, and Digital Pathology Model Improves Risk Stratification and Refines Chemotherapy Benefit Prediction in TAILORx

Ngoc Kim Nguyen, University of Chicago, Chicago, IL